Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

NCT05350189
completed

Drug Use Investigation of Gadovist.

NCT02540967
completedphase_4

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
completedphase_2

Myocardial Perfusion MRI

NCT01490294

Clinical Trials (4)

Showing 4 of 4 trials
NCT05350189

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Completed
NCT02540967

Drug Use Investigation of Gadovist.

Completed
NCT03602339Phase 4

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Completed
NCT01490294Phase 2

Myocardial Perfusion MRI

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4